Pre-Long Weekend Clean-Up: Etugliflozin News Due From Merck/Pfizer 60/40 Venture, In Early June…
May 17, 2017

This falls in the diabetes space, for the two companies — which as we reported almost exactly four years ago — involves a 60/40 split, in favor of Kenilworth, on this next gen Phase III candidate.

To be fair, this cooperative effort is running well behind the Lilly offering (in fact, we speculated that the entire “risk sharing” venture was born of Lilly’s clear lead, back in the Spring of 2013). Merck does expect to report news (on this, and a host of other diabetes-focused studies) in early June at the ADA conference in San Diego — so that is potentially good news. Here’s the bit:

. . .Merck announced that 19 scientific presentations from Merck’s diabetes pipeline and portfolio – including Phase 3 data for investigational ertugliflozin, additional analyses of JANUVIA® (sitagliptin), and real-world research – will be presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) in San Diego, June 9-13, 2017. Oral and poster presentations of ertugliflozin, a SGLT-2 inhibitor in development with Pfizer, include new data from two Phase 3 studies and 52-week extension data from three other studies in the VERTIS clinical development program.. . . .

Now you know. Scantly sleeping, once again, as sleep fails to find me. . . oh well.

नमस्ते